Monoglyceride Lipase (MGLL) (Middle Region) Peptide
-
- Target See all MGLL products
- MGLL (Monoglyceride Lipase (MGLL))
- Protein Region
- Middle Region
- Origin
- Human, Rat
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Western Blotting (WB)
- Sequence
- PKALIFVSHG AGEHCGRYDE LAQMLKRLDM LVFAHDHVGH GQSEGERMVV
- Characteristics
- This is a synthetic peptide designed for use in combination with anti-Mgll Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- Purification
- Purified
-
-
- Application Notes
- Optimal working dilution should be determined by the investigator.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Concentration
- 1 mg/mL
- Buffer
- Final peptide concentration is 1 mg/mL in PBS.
- Handling Advice
- Avoid repeat freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- MGLL (Monoglyceride Lipase (MGLL))
- Background
-
Mgll converts monoacylglycerides to free fatty acids and glycerol. Mgll hydrolyzes the endocannabinoid 2-arachidonoylglycerol, and thereby contributes to the regulation of endocannabinoid signaling, nociperception and perception of pain. It regulates the levels of fatty acids that serve as signaling molecules and promote cancer cell migration, invasion and tumor growth.
Alias Symbols: MAGL
Protein Size: 303 - Molecular Weight
- 33 kDa
- Gene ID
- 29254
- NCBI Accession
- NM_138502, NP_612511
- UniProt
- Q8R431
-